IBDEI343 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,49698,1,3,0)
 ;;=3^Chronic Kidney Disease,Stage 5
 ;;^UTILITY(U,$J,358.3,49698,1,4,0)
 ;;=4^N18.5
 ;;^UTILITY(U,$J,358.3,49698,2)
 ;;=^5015606
 ;;^UTILITY(U,$J,358.3,49699,0)
 ;;=N18.6^^191^2478^22
 ;;^UTILITY(U,$J,358.3,49699,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49699,1,3,0)
 ;;=3^End Stage Renal Disease
 ;;^UTILITY(U,$J,358.3,49699,1,4,0)
 ;;=4^N18.6
 ;;^UTILITY(U,$J,358.3,49699,2)
 ;;=^303986
 ;;^UTILITY(U,$J,358.3,49700,0)
 ;;=J96.11^^191^2478^19
 ;;^UTILITY(U,$J,358.3,49700,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49700,1,3,0)
 ;;=3^Chronic Respiratory Failure w/ Hypoxia
 ;;^UTILITY(U,$J,358.3,49700,1,4,0)
 ;;=4^J96.11
 ;;^UTILITY(U,$J,358.3,49700,2)
 ;;=^5008351
 ;;^UTILITY(U,$J,358.3,49701,0)
 ;;=J44.9^^191^2478^12
 ;;^UTILITY(U,$J,358.3,49701,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49701,1,3,0)
 ;;=3^COPD,Unspec
 ;;^UTILITY(U,$J,358.3,49701,1,4,0)
 ;;=4^J44.9
 ;;^UTILITY(U,$J,358.3,49701,2)
 ;;=^5008241
 ;;^UTILITY(U,$J,358.3,49702,0)
 ;;=E44.0^^191^2478^29
 ;;^UTILITY(U,$J,358.3,49702,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49702,1,3,0)
 ;;=3^Moderate Protein-Calorie Malnutrition
 ;;^UTILITY(U,$J,358.3,49702,1,4,0)
 ;;=4^E44.0
 ;;^UTILITY(U,$J,358.3,49702,2)
 ;;=^5002787
 ;;^UTILITY(U,$J,358.3,49703,0)
 ;;=E43.^^191^2478^30
 ;;^UTILITY(U,$J,358.3,49703,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49703,1,3,0)
 ;;=3^Severe Protein-Calorie Malnutrition
 ;;^UTILITY(U,$J,358.3,49703,1,4,0)
 ;;=4^E43.
 ;;^UTILITY(U,$J,358.3,49703,2)
 ;;=^5002786
 ;;^UTILITY(U,$J,358.3,49704,0)
 ;;=R64.^^191^2478^13
 ;;^UTILITY(U,$J,358.3,49704,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49704,1,3,0)
 ;;=3^Cachexia
 ;;^UTILITY(U,$J,358.3,49704,1,4,0)
 ;;=4^R64.
 ;;^UTILITY(U,$J,358.3,49704,2)
 ;;=^17920
 ;;^UTILITY(U,$J,358.3,49705,0)
 ;;=I10.^^191^2478^23
 ;;^UTILITY(U,$J,358.3,49705,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49705,1,3,0)
 ;;=3^Essential (Primary) Hypertension
 ;;^UTILITY(U,$J,358.3,49705,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,49705,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,49706,0)
 ;;=I25.10^^191^2478^11
 ;;^UTILITY(U,$J,358.3,49706,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49706,1,3,0)
 ;;=3^CAD w/o Angina Pectoris
 ;;^UTILITY(U,$J,358.3,49706,1,4,0)
 ;;=4^I25.10
 ;;^UTILITY(U,$J,358.3,49706,2)
 ;;=^5007107
 ;;^UTILITY(U,$J,358.3,49707,0)
 ;;=E78.2^^191^2478^28
 ;;^UTILITY(U,$J,358.3,49707,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49707,1,3,0)
 ;;=3^Mixed Hyperlipidemia
 ;;^UTILITY(U,$J,358.3,49707,1,4,0)
 ;;=4^E78.2
 ;;^UTILITY(U,$J,358.3,49707,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,49708,0)
 ;;=I48.0^^191^2478^8
 ;;^UTILITY(U,$J,358.3,49708,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49708,1,3,0)
 ;;=3^Atrial Fibrillation,Paroxysmal
 ;;^UTILITY(U,$J,358.3,49708,1,4,0)
 ;;=4^I48.0
 ;;^UTILITY(U,$J,358.3,49708,2)
 ;;=^90473
 ;;^UTILITY(U,$J,358.3,49709,0)
 ;;=I48.11^^191^2478^6
 ;;^UTILITY(U,$J,358.3,49709,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49709,1,3,0)
 ;;=3^Atrial Fibrillation,Longstanding Persistent
 ;;^UTILITY(U,$J,358.3,49709,1,4,0)
 ;;=4^I48.11
 ;;^UTILITY(U,$J,358.3,49709,2)
 ;;=^5158046
 ;;^UTILITY(U,$J,358.3,49710,0)
 ;;=I48.19^^191^2478^7
 ;;^UTILITY(U,$J,358.3,49710,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,49710,1,3,0)
 ;;=3^Atrial Fibrillation,Other Persistent
 ;;^UTILITY(U,$J,358.3,49710,1,4,0)
 ;;=4^I48.19
